Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Short-term Investments (2022 - 2025)

ARS Pharmaceuticals' Short-term Investments history spans 4 years, with the latest figure at $203.7 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 22.62% year-over-year to $203.7 million; the TTM value through Dec 2025 reached $203.7 million, down 22.62%, while the annual FY2025 figure was $203.7 million, 22.62% down from the prior year.
  • Short-term Investments for Q4 2025 was $203.7 million at ARS Pharmaceuticals, down from $228.7 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $263.2 million in Q4 2024 and bottomed at $19.9 million in Q1 2022.
  • The 4-year median for Short-term Investments is $172.2 million (2023), against an average of $154.4 million.
  • The largest annual shift saw Short-term Investments soared 789.75% in 2023 before it dropped 22.62% in 2025.
  • A 4-year view of Short-term Investments shows it stood at $63.9 million in 2022, then skyrocketed by 146.45% to $157.4 million in 2023, then surged by 67.23% to $263.2 million in 2024, then fell by 22.62% to $203.7 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Short-term Investments are $203.7 million (Q4 2025), $228.7 million (Q3 2025), and $188.6 million (Q2 2025).